No psychedelic biotech will see sustained rally absent a Phase 3 readout or FDA decision this year.

Stock prices for psychedelic drug companies are unlikely to climb and stay up in 2024 unless one of them publishes strong results from a large late-stage clinical trial or gets a formal decision from the FDA. News about laws or personal healing stories doesn't persuade big institutional investors to move serious money. Only hard clinical proof does.

Legislative noise and retreat stories don't move institutional capital. Only de-risked catalysts do, and none are imminent.